Literature DB >> 28179447

DIAGNOSIS OF ENDOCRINE DISEASE: Differentiation of pathologic/neoplastic hypercortisolism (Cushing's syndrome) from physiologic/non-neoplastic hypercortisolism (formerly known as pseudo-Cushing's syndrome).

James W Findling1, Hershel Raff2.   

Abstract

Endogenous hypercortisolism (Cushing's syndrome) usually implies the presence of a pathologic condition caused by either an ACTH-secreting neoplasm or autonomous cortisol secretion from a benign or malignant adrenal neoplasm. However, sustained or intermittent hypercortisolism may also accompany many medical disorders that stimulate physiologic/non-neoplastic activation of the HPA axis (formerly known as pseudo-Cushing's syndrome); these two entities may share indistinguishable clinical and biochemical features. A thorough history and physical examination is often the best (and sometimes only) way to exclude pathologic/neoplastic hypercortisolism. The presence of alcoholism, renal failure, poorly controlled diabetes and severe neuropsychiatric disorders should always raise suspicion that the presence of hypercortisolism may be related to physiologic/non-neoplastic Cushing's syndrome. As late-night salivary cortisol and low-dose dexamethasone suppression have good sensitivity and negative predictive value, normal studies exclude Cushing's syndrome of any form. However, these tests have imperfect specificity and additional testing over time with clinical follow-up is often needed. When there is persistent diagnostic uncertainty, secondary tests such as the DDAVP stimulation test and the dexamethasone-CRH test may provide evidence for the presence or absence of an ACTH-secreting tumor. This review will define and characterize the numerous causes of physiologic/non-neoplastic hypercortisolism and provide a rational clinical and biochemical approach to distinguish it from pathologic/neoplastic hypercortisolism (true Cushing's syndrome).
© 2017 European Society of Endocrinology.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28179447     DOI: 10.1530/EJE-16-0946

Source DB:  PubMed          Journal:  Eur J Endocrinol        ISSN: 0804-4643            Impact factor:   6.664


  24 in total

Review 1.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

2.  Pituitary-adrenal axis and peripheral cortisol metabolism in obese patients.

Authors:  Filippo Ceccato; Laura Lizzul; Mattia Barbot; Carla Scaroni
Journal:  Endocrine       Date:  2020-06-20       Impact factor: 3.633

3.  Early post-natal life stress induces permanent adrenocorticotropin-dependent hypercortisolism in male mice.

Authors:  Luca Persani; Iacopo Chiodini; Gabriele Campana; Stefano Loizzo; Andrea Fortuna; Roberto Rimondini; Zaira Maroccia; Alfredo Scillitani; Alberto Falchetti; Santi Mario Spampinato
Journal:  Endocrine       Date:  2021-02-25       Impact factor: 3.633

Review 4.  Consensus on diagnosis and management of Cushing's disease: a guideline update.

Authors:  Maria Fleseriu; Richard Auchus; Irina Bancos; Anat Ben-Shlomo; Jerome Bertherat; Nienke R Biermasz; Cesar L Boguszewski; Marcello D Bronstein; Michael Buchfelder; John D Carmichael; Felipe F Casanueva; Frederic Castinetti; Philippe Chanson; James Findling; Mônica Gadelha; Eliza B Geer; Andrea Giustina; Ashley Grossman; Mark Gurnell; Ken Ho; Adriana G Ioachimescu; Ursula B Kaiser; Niki Karavitaki; Laurence Katznelson; Daniel F Kelly; André Lacroix; Ann McCormack; Shlomo Melmed; Mark Molitch; Pietro Mortini; John Newell-Price; Lynnette Nieman; Alberto M Pereira; Stephan Petersenn; Rosario Pivonello; Hershel Raff; Martin Reincke; Roberto Salvatori; Carla Scaroni; Ilan Shimon; Constantine A Stratakis; Brooke Swearingen; Antoine Tabarin; Yutaka Takahashi; Marily Theodoropoulou; Stylianos Tsagarakis; Elena Valassi; Elena V Varlamov; Greisa Vila; John Wass; Susan M Webb; Maria C Zatelli; Beverly M K Biller
Journal:  Lancet Diabetes Endocrinol       Date:  2021-10-20       Impact factor: 32.069

5.  Patient reported outcomes and treatment satisfaction in patients with cushing syndrome.

Authors:  Maureen Rakovec; William Zhu; Adham M Khalafallah; Roberto Salvatori; Amir H Hamrahian; Gary L Gallia; Masaru Ishii; Nyall R London; Murugappan Ramanathan; Nicholas R Rowan; Debraj Mukherjee
Journal:  Endocrine       Date:  2022-10-13       Impact factor: 3.925

6.  How to rule out non-neoplastic hypercortisolemia (previously known as pseudo-cushing).

Authors:  Carla Scaroni; Alessandro Mondin; Filippo Ceccato
Journal:  Pituitary       Date:  2022-05-26       Impact factor: 3.599

Review 7.  Molecular Derangements and the Diagnosis of ACTH-Dependent Cushing's Syndrome.

Authors:  Lynnette K Nieman
Journal:  Endocr Rev       Date:  2022-09-26       Impact factor: 25.261

Review 8.  TREATMENT OF CUSHING'S SYNDROME : WHAT PLACE FOR MEDICAL TREATMENT?

Authors:  O Chabre; J Cristante
Journal:  Acta Endocrinol (Buchar)       Date:  2019 Apr-Jun       Impact factor: 0.877

Review 9.  Pitfalls in Performing and Interpreting Inferior Petrosal Sinus Sampling: Personal Experience and Literature Review.

Authors:  Jordan E Perlman; Philip C Johnston; Ferdinand Hui; Guy Mulligan; Robert J Weil; Pablo F Recinos; Divya Yogi-Morren; Roberto Salvatori; Debraj Mukherjee; Gary Gallia; Laurence Kennedy; Amir H Hamrahian
Journal:  J Clin Endocrinol Metab       Date:  2021-04-23       Impact factor: 5.958

Review 10.  Cyclic Cushing's Syndrome - A Diagnostic Challenge.

Authors:  Renata Świątkowska-Stodulska; Agata Berlińska; Katarzyna Stefańska; Przemysław Kłosowski; Krzysztof Sworczak
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-22       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.